{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:21:07Z","timestamp":1787678467013,"version":"build-2784847793"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijbiomac.2026.153092","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:11:48Z","timestamp":1781935908000},"page":"153092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting HIV-1 integrase: A review of options, challenges and future directions"],"prefix":"10.1016","volume":"372","author":[{"given":"Rebecca A.","family":"Bourquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.153092_bb0005","series-title":"Latest HIV Estimates and Updates on HIV Policies Uptake","volume":"2021","author":"World Health Organisation","year":"2021"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000445852","article-title":"Human immunodeficiency virus (HIV)","volume":"43","author":"S.A.o.P.T.b.B. German Advisory Committee Blood","year":"2016","journal-title":"Transfus. Med. Hemother."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1473-3099(18)30647-9","article-title":"Global and regional molecular epidemiology of HIV-1, 1990\u20132015: a systematic review, global survey, and trend analysis","volume":"19","author":"Hemelaar","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0268-960X(90)90043-R","article-title":"Human immunodeficiency virus type 2 (HIV2)","volume":"4","author":"Hughes","year":"1990","journal-title":"Blood Rev."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153092_bb0025","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.tim.2008.09.003","article-title":"HIV-2: the forgotten AIDS virus","volume":"16","author":"de Silva","year":"2008","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0030","author":"World Health Organisation"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0035","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40121-024-00982-7","article-title":"Clinical outcomes of integrase strand transfer inhibitors containing antiretroviral therapy in HIV-2: a narrative review","volume":"13","author":"Boschloo","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.biochem.67.1.1","article-title":"HIV-1: fifteen proteins and an RNA","volume":"67","author":"Frankel","year":"1998","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0045","first-page":"70","article-title":"The HIV-1 passage from cytoplasm to nucleus: the process involving a complex exchange between the components of HIV-1 and cellular machinery to access nucleus and successful integration","volume":"3","author":"Jayappa","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0050","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/0092-8674(91)90297-C","article-title":"HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer","volume":"67","author":"Engelman","year":"1991","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000046","article-title":"The lentiviral integrase binding protein LEDGF\/p75 and HIV-1 replication","volume":"4","author":"Engelman","year":"2008","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153092_bb0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA-J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0065","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.153092_bb0070","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/acs.biochem.1c00157","article-title":"Long-acting cabotegravir for HIV\/AIDS prophylaxis","volume":"60","author":"Engelman","year":"2021","journal-title":"Biochemistry"},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.153092_bb0075","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1073\/pnas.95.16.9150","article-title":"Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium","volume":"95","author":"Goldgur","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.153092_bb0080","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1073\/pnas.87.13.5119","article-title":"Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity","volume":"87","author":"Sherman","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biom10091236","article-title":"A fluorescent assay to search for inhibitors of HIV-1 integrase interactions with human Ku70 protein, and its application for characterization of oligonucleotide inhibitors","volume":"10","author":"Galkin","year":"2020","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0090","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.virol.2012.09.033","article-title":"The LEDGF\/p75 integrase interaction, a novel target for anti-HIV therapy","volume":"435","author":"Christ","year":"2013","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153092_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2024.168557","article-title":"HIV-1 integrase assembles multiple species of stable synaptic complex intasomes that are active for concerted DNA integration in vitro","volume":"436","author":"Li","year":"2024","journal-title":"J. Mol. Biol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153092_bb0100","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1002\/j.1460-2075.1993.tb05996.x","article-title":"Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex","volume":"12","author":"Engelman","year":"1993","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0105","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/nar\/21.6.1419","article-title":"Identification of the catalytic and DNA-binding region of the human-immunodeficiency-virus type-I integrase protein","volume":"21","author":"Vink","year":"1993","journal-title":"Nucleic Acids Res."},{"issue":"6320","key":"10.1016\/j.ijbiomac.2026.153092_bb0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.aah5163","article-title":"Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome","volume":"355","author":"Passos","year":"2017","journal-title":"Science"},{"issue":"6479","key":"10.1016\/j.ijbiomac.2026.153092_bb0115","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1126\/science.aay8015","article-title":"Structural basis for strand-transfer inhibitor binding to HIV intasomes","volume":"367","author":"Passos","year":"2020","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/febs.15438","article-title":"Close-up: HIV\/SIV intasome structures shed new light on integrase inhibitor binding and viral escape mechanisms","volume":"288","author":"Engelman","year":"2021","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153092_bb0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(02)00864-4","article-title":"HIV-1 integration in the human genome favors active genes and local hotspots","volume":"110","author":"Schroder","year":"2002","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153092_bb0130","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/fvl.12.56","article-title":"The molecular biology of HIV integrase","volume":"7","author":"Craigie","year":"2012","journal-title":"Future Virol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41467-019-08333-8","article-title":"Physical principles of retroviral integration in the human genome","volume":"10","author":"Michieletto","year":"2019","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.153092_bb0140","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1101\/gad.267609.115","article-title":"LEDGF\/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes","volume":"29","author":"Singh","year":"2015","journal-title":"Genes Dev."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153092_bb0145","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1093\/nar\/gku136","article-title":"Integrase residues that determine nucleotide preferences at sites of HIV-1 integration: implications for the mechanism of target DNA binding","volume":"42","author":"Serrao","year":"2014","journal-title":"Nucleic Acids Res."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.153092_bb0150","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.1073\/pnas.0501646102","article-title":"Symmetrical base preferences surrounding HIV-1, avian sarcoma\/leukosis virus, and murine leukemia virus integration sites","volume":"102","author":"Holman","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0155","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41586-026-10154-x","article-title":"Integrase anchors viral RNA to the HIV-1 capsid interior","volume":"652","author":"Singer","year":"2026","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0160","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2016.07.044","article-title":"HIV-1 integrase binds the viral RNA genome and is essential during virion morphogenesis","volume":"166","author":"Kessl","year":"2016","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/v12091005","article-title":"Going beyond integration: the emerging role of HIV-1 integrase in virion morphogenesis","volume":"12","author":"Elliott","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0170","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54311","article-title":"Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis","volume":"9","author":"Elliott","year":"2020","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153092_bb0175","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fvl-2019-0077","article-title":"Update on HIV integrase inhibitors for the treatment of HIV-1 infection","volume":"14","author":"Max","year":"2019","journal-title":"Future Virol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153092_bb0180","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1073\/pnas.1112389109","article-title":"Probing chelation motifs in HIV integrase inhibitors","volume":"109","author":"Agrawal","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4882","key":"10.1016\/j.ijbiomac.2026.153092_bb0185","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1126\/science.2460925","article-title":"The accuracy of reverse transcriptase from HIV-1","volume":"242","author":"Roberts","year":"1988","journal-title":"Science"},{"issue":"5453","key":"10.1016\/j.ijbiomac.2026.153092_bb0190","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"Hazuda","year":"2000","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.153092_bb0195","doi-asserted-by":"crossref","first-page":"11244","DOI":"10.1073\/pnas.200139397","article-title":"HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase","volume":"97","author":"Espeseth","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153092_bb0200","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1073\/pnas.092056199","article-title":"Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes","volume":"99","author":"Grobler","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.153092_bb0205","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"Summa","year":"2008","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals","volume":"43","author":"Markowitz","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"9569","key":"10.1016\/j.ijbiomac.2026.153092_bb0215","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial","volume":"369","author":"Grinsztejn","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153092_bb0220","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153092_bb0225","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials","volume":"50","author":"Steigbigel","year":"2010","journal-title":"Clin. Infect. Dis."},{"issue":"9712","key":"10.1016\/j.ijbiomac.2026.153092_bb0230","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0235","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0240","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1021\/jm0600139","article-title":"Novel HIV-1 integrase inhibitors derived from quinolone antibiotics","volume":"49","author":"Sato","year":"2006","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0245","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1128\/AAC.06170-11","article-title":"Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens","volume":"56","author":"Garrido","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.153092_bb0250","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1021\/jm3010459","article-title":"Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore","volume":"55","author":"Kawasuji","year":"2012","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0255","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/jm301550c","article-title":"Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles","volume":"56","author":"Kawasuji","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0260","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.bmcl.2012.11.071","article-title":"Naphthyridinone (NTD) integrase inhibitors: N1 protio and methyl combination substituent effects with C3 amide groups","volume":"23","author":"Johns","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0265","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0270","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.antiviral.2011.03.178","article-title":"Resistance associated mutations to dolutegravir (S\/GSK1349572) in HIV-infected patients\u2014impact of HIV subtypes and prior raltegravir experience","volume":"90","author":"Garrido","year":"2011","journal-title":"Antivir. Res."},{"issue":"29","key":"10.1016\/j.ijbiomac.2026.153092_bb0275","doi-asserted-by":"crossref","first-page":"eadg5953","DOI":"10.1126\/sciadv.adg5953","article-title":"Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0280","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02406-20","article-title":"Long dissociation of bictegravir from HIV-1 integrase-DNA complexes","volume":"65","author":"White","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0285","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","article-title":"Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults","volume":"75","author":"Gallant","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153092_bb0290","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/infdis\/jiy428","article-title":"Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors","volume":"218","author":"Zhang","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0295","author":"Food and Drug Administration"},{"issue":"10267","key":"10.1016\/j.ijbiomac.2026.153092_bb0300","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0305","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40271-021-00524-0","article-title":"Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M)","volume":"14","author":"Chounta","year":"2021","journal-title":"Patient"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153092_bb0310","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0315","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/s41467-019-10047-w","article-title":"Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection","volume":"10","author":"Radzio-Basu","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms13020321","article-title":"Drug resistance mutations (DRMs) for long-acting injectable cabotegravir and rilpivirine (CAB\/RPV LAI) in the HIV-1 subtype A6 epidemic in Poland","volume":"13","author":"Zaleski","year":"2025","journal-title":"Microorganisms"},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.153092_bb0325","doi-asserted-by":"crossref","first-page":"e596","DOI":"10.1093\/ajhp\/zxaf078","article-title":"Cabotegravir\/rilpivirine resistance in a patient living with HIV despite on-time administration: a case report","volume":"82","author":"Towne","year":"2025","journal-title":"Am. J. Health-Syst. Pharm."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0330","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/cid\/ciae631","article-title":"Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long-acting cabotegravir for HIV treatment: a meta-analysis","volume":"81","author":"Perez Navarro","year":"2025","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0335","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/10600280241257656","article-title":"A case of E138K cabotegravir\/rilpivirine resistance: challenges and concerns when persons living with HIV relocate","volume":"59","author":"Pecora Fulco","year":"2025","journal-title":"Ann. Pharmacother."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0340","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/14787210.2025.2529431","article-title":"How frequent is dolutegravir resistance?","volume":"23","author":"van Osch","year":"2025","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0345","first-page":"457","article-title":"2025 update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing","year":"2025","journal-title":"Top. Antivir. Med."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153092_bb0350","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153092_bb0355","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1093\/jac\/dkz256","article-title":"A systematic review of the genetic mechanisms of dolutegravir resistance","volume":"74","author":"Rhee","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153092_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040514","article-title":"Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations","volume":"7","author":"Winters","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153092_bb0365","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/QAI.0b013e3181c9c967","article-title":"Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study","volume":"53","author":"Gatell","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0370","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012","volume":"58","author":"Hurt","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153092_bb0375","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"Aids"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0380","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153092_bb0385","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/jac\/dkr389","article-title":"The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype","volume":"66","author":"Malet","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153092_bb0390","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/jac\/dkw071","article-title":"Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors","volume":"71","author":"Brenner","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0395","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study","volume":"207","author":"Eron","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153092_bb0400","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/jac\/dky093","article-title":"Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial","volume":"73","author":"Blanco","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0405","doi-asserted-by":"crossref","DOI":"10.1186\/1742-4690-10-22","article-title":"Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure","volume":"10","author":"Mesplede","year":"2013","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0410","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2011.12.008","article-title":"In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4","volume":"93","author":"Margot","year":"2012","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0415","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cid\/ciaf135","article-title":"Phase 1 evaluation of VH4524184, a third-generation integrase strand transfer inhibitor with an enhanced resistance profile","volume":"81","author":"Rogg","year":"2025","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0420","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41467-026-68501-5","article-title":"An ultra-long-acting dimeric bictegravir prodrug defined by a short pharmacokinetic tail","volume":"17","author":"Nayan","year":"2026","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153092_bb0425","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1021\/ml500002n","article-title":"Discovery of BI 224436, a noncatalytic site integrase inhibitor (NCINI) of HIV-1","volume":"5","author":"Fader","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0430","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1128\/AAC.02719-13","article-title":"Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor","volume":"58","author":"Fenwick","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116900","article-title":"A mini-review on integrase inhibitors: the cornerstone of next-generation HIV treatment","volume":"279","author":"Shalbi","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.153092_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2025.169224","article-title":"Structural impact of ex vivo resistance mutations on HIV-1 integrase polymers induced by allosteric inhibitors","volume":"437","author":"Montermoso","year":"2025","journal-title":"J. Mol. Biol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0445","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1021\/acsmedchemlett.4c00268","article-title":"Quinolinonyl derivatives as dual inhibitors of the HIV-1 integrase catalytic site and integrase-RNA interactions","volume":"15","author":"Patacchini","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.153092_bb0450","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1073\/pnas.1300703110","article-title":"Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation","volume":"110","author":"Jurado","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153092_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009671","article-title":"A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF\/p75-integrase interaction site","volume":"17","author":"Maehigashi","year":"2021","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0460","doi-asserted-by":"crossref","first-page":"e0356022","DOI":"10.1128\/mbio.03560-22","article-title":"The drug-induced interface that drives HIV-1 integrase hypermultimerization and loss of function","volume":"14","author":"Singer","year":"2023","journal-title":"mBio"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153092_bb0465","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00465-24","article-title":"The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir","volume":"15","author":"Dinh","year":"2024","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153092_bb0470","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03106-25","article-title":"Erratum for Dinh et al., \u201cThe structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir\u201d","volume":"16","author":"Dinh","year":"2025","journal-title":"mBio"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0475","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/nar\/22.6.1121","article-title":"A novel assay for the DNA strand-transfer reaction of HIV-1 integrase","volume":"22","author":"Hazuda","year":"1994","journal-title":"Nucleic Acids Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0480","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0485","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1021\/acs.jcim.7b00402","article-title":"Discovery of a novel HIV-1 integrase\/p75 interacting inhibitor by docking screening, biochemical assay, and in vitro studies","volume":"57","author":"Wang","year":"2017","journal-title":"J. Chem. Inf. Model."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.153092_bb0490","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1080\/07391102.2018.1557559","article-title":"The design of potent HIV-1 integrase inhibitors by a combined approach of structure-based virtual screening and molecular dynamics simulation","volume":"37","author":"Samorlu","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0495","article-title":"Development and validation of a machine learning model for identifying novel HIV integrase inhibitors","volume":"17","author":"Mukuhlani","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0500","article-title":"Discovery of new anti-HIV candidate molecules with an AI-based multi-stage system approach using molecular docking and ADME predictions","volume":"267","author":"Harun","year":"2025","journal-title":"Chemom. Intell. Lab. Syst."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.153092_bb0505","doi-asserted-by":"crossref","first-page":"14506","DOI":"10.1039\/D4RA02231A","article-title":"Novel machine learning approach toward classification model of HIV-1 integrase inhibitors","volume":"14","author":"Phan","year":"2024","journal-title":"RSC Adv."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0510","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1080\/07391102.2022.2028677","article-title":"Repurposing FDA-approved drugs as HIV-1 integrase inhibitors: an in silico investigation","volume":"41","author":"Ha","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0515","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/1062936X.2022.2057588","article-title":"Machine learning-based predictive models for identifying high active compounds against HIV-1 integrase","volume":"33","author":"Parvez","year":"2022","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0520","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5559338","article-title":"Classification and design of HIV-1 integrase inhibitors based on machine learning","volume":"2021","author":"Zhou","year":"2021","journal-title":"Comput. Math. Methods Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153092_bb0525","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1073\/pnas.88.4.1339","article-title":"Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA","volume":"88","author":"Bushman","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0530","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/1087057105276318","article-title":"Development and application of a high-throughput screening assay for HIV-1 integrase enzyme activities","volume":"10","author":"John","year":"2005","journal-title":"J. Biomol. Screen."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153092_bb0535","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1093\/nar\/22.11.2176","article-title":"A high-throughput, non-radioactive microtiter plate assay for activity of the human immunodeficiency virus integrase protein","volume":"22","author":"Vink","year":"1994","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153092_bb0540","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.biochi.2012.06.009","article-title":"A new fluorometric assay for the study of DNA-binding and 3\u2032-processing activities of retroviral integrases and its use for screening of HIV-1 integrase inhibitors","volume":"94","author":"Anisenko","year":"2012","journal-title":"Biochimie"},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.153092_bb0545","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1093\/nar\/23.15.2872","article-title":"Incorporation of a fluorescent guanosine analog into oligonucleotides and its application to a real time assay for the HIV-1 integrase 3\u2032-processing reaction","volume":"23","author":"Hawkins","year":"1995","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0550","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/1087057105275212","article-title":"Homogeneous high-throughput screening assays for HIV-1 integrase 3beta-processing and strand transfer activities","volume":"10","author":"Wang","year":"2005","journal-title":"J. Biomol. Screen."},{"issue":"32","key":"10.1016\/j.ijbiomac.2026.153092_bb0555","doi-asserted-by":"crossref","first-page":"22707","DOI":"10.1074\/jbc.M602198200","article-title":"Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity","volume":"281","author":"Guiot","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153092_bb0560","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ymeth.2008.10.024","article-title":"Oligonucleotide-based assays for integrase activity","volume":"47","author":"Merkel","year":"2009","journal-title":"Methods"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0565","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1745-7254.2007.00561.x","article-title":"High-throughput real-time assay based on molecular beacons for HIV-1 integrase 3\u2032-processing reaction","volume":"28","author":"He","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2026.153092_bb0570","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jviromet.2012.05.003","article-title":"A high-throughput assay for HIV-1 integrase 3\u2032-processing activity using time-resolved fluorescence","volume":"184","author":"Han","year":"2012","journal-title":"J. Virol. Methods"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0575","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.antiviral.2013.04.001","article-title":"Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors","volume":"98","author":"Han","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0580","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/853891","article-title":"Novel 3\u2019-processing integrase activity assay by real-time PCR for screening and identification of HIV-1 integrase inhibitors","volume":"2015","author":"Sakkhachornphop","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153092_bb0585","doi-asserted-by":"crossref","first-page":"12331","DOI":"10.1021\/acs.jmedchem.4c03115","article-title":"Target engagement assays in early drug discovery","volume":"68","author":"St John-Campbell","year":"2025","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.153092_bb0590","doi-asserted-by":"crossref","first-page":"18727","DOI":"10.1021\/acs.jmedchem.5c02336","article-title":"Correction to \u201ctarget engagement assays in early drug discovery\u201d","volume":"68","author":"St John-Campbell","year":"2025","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0595","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.coviro.2012.08.005","article-title":"The future of integrase inhibitors of HIV-1","volume":"2","author":"Malet","year":"2012","journal-title":"Curr. Opin. Virol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0600","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/1087057108317060","article-title":"Screening for antiviral inhibitors of the HIV integrase-LEDGF\/p75 interaction using the AlphaScreen luminescent proximity assay","volume":"13","author":"Hou","year":"2008","journal-title":"J. Biomol. Screen."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0605","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/1087057111436343","article-title":"Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitors","volume":"17","author":"Demeulemeester","year":"2012","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0610","article-title":"A novel assay for screening inhibitors targeting HIV-1 integrase dimerization based on Ni-NTA magnetic agarose beads","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0615","doi-asserted-by":"crossref","DOI":"10.1038\/srep33477","article-title":"A novel assay for screening inhibitors targeting HIV integrase LEDGF\/p75 interaction based on Ni(2+) coated magnetic agarose beads","volume":"6","author":"Dawei","year":"2016","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0620","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1039\/C1RA00582K","article-title":"De novo design of small molecule inhibitors targeting the LEDGF\/p75-HIV integrase interaction","volume":"2","author":"Cavalluzzo","year":"2012","journal-title":"RSC Adv."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153092_bb0625","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/psc.2543","article-title":"Identification of small peptides inhibiting the integrase-LEDGF\/p75 interaction through targeting the cellular co-factor","volume":"19","author":"Cavalluzzo","year":"2013","journal-title":"J. Pept. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0630","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bbrc.2008.07.139","article-title":"D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF\/p75","volume":"375","author":"Du","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.153092_bb0635","doi-asserted-by":"crossref","first-page":"17722","DOI":"10.1074\/jbc.M110.184739","article-title":"Host protein Ku70 binds and protects HIV-1 integrase from proteasomal degradation and is required for HIV replication","volume":"286","author":"Zheng","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0640","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12977-019-0492-z","article-title":"NHEJ pathway is involved in post-integrational DNA repair due to Ku70 binding to HIV-1 integrase","volume":"16","author":"Knyazhanskaya","year":"2019","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0645","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1038\/s41598-017-05659-5","article-title":"Characterization of HIV-1 integrase interaction with human Ku70 protein and initial implications for drug targeting","volume":"7","author":"Anisenko","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0650","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/jvi.71.9.7005-7011.1997","article-title":"Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase","volume":"71","author":"Hazuda","year":"1997","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.ijbiomac.2026.153092_bb0655","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1093\/nar\/28.24.4884","article-title":"Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor isolation","volume":"28","author":"Hwang","year":"2000","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0660","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/108705702760047754","article-title":"Microarray compound screening (microARCS) to identify inhibitors of HIV integrase","volume":"7","author":"David","year":"2002","journal-title":"J. Biomol. Screen."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0665","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/095632020501600603","article-title":"A novel small molecular weight compound with a carbazole structure that demonstrates potent human immunodeficiency virus type-1 integrase inhibitory activity","volume":"16","author":"Yan","year":"2005","journal-title":"Antivir. Chem. Chemother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0670","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1745-7254.2008.00748.x","article-title":"A novel high-throughput format assay for HIV-1 integrase strand transfer reaction using magnetic beads","volume":"29","author":"He","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"issue":"5045","key":"10.1016\/j.ijbiomac.2026.153092_bb0675","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1126\/science.1738845","article-title":"Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus","volume":"255","author":"Chow","year":"1992","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0680","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11427-010-0006-7","article-title":"Development of a high-throughput assay for the HIV-1 integrase disintegration reaction","volume":"53","author":"He","year":"2010","journal-title":"Sci. China Life Sci."},{"issue":"3\u20134","key":"10.1016\/j.ijbiomac.2026.153092_bb0685","article-title":"Screening of the NIH clinical collection for inhibitors of HIV-1 integrase activity","volume":"114","author":"Abrahams","year":"2018","journal-title":"S. Afr. J. Sci."},{"issue":"Pt 3","key":"10.1016\/j.ijbiomac.2026.153092_bb0690","article-title":"Fluorescent HIV-1 integrases for a suite of new user-friendly stability, nucleic acid binding and strand transfer activity assays","volume":"309","author":"Bourquin","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0695","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1039\/C5AY03064A","article-title":"Green fluorescent protein-based assays for high-throughput functional characterization and ligand-binding studies of biotin protein ligase","volume":"8","author":"Askin","year":"2016","journal-title":"Anal. Methods"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153092_bb0700","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1039\/D4SD00225C","article-title":"A self-assembling protein-DNA complex with an inbuilt DNA release system for quantitative immuno-PCR applications","volume":"3","author":"Sorenson","year":"2024","journal-title":"Sens. Diagn."},{"issue":"Pt 4","key":"10.1016\/j.ijbiomac.2026.153092_bb0705","article-title":"High-performance hairpin-whiptail DNA target for HIV-1 integrase assay","volume":"318","author":"Bourquin","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153092_bb0710","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1128\/JVI.79.8.5211-5214.2005","article-title":"Weak palindromic consensus sequences are a common feature found at the integration target sites of many retroviruses","volume":"79","author":"Wu","year":"2005","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153092_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081184","article-title":"Natural stilbenoids isolated from grapevine exhibiting inhibitory effects against HIV-1 integrase and eukaryote MOS1 transposase in vitro activities","volume":"8","author":"Pflieger","year":"2013","journal-title":"PloS One"},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.153092_bb0720","doi-asserted-by":"crossref","first-page":"16801","DOI":"10.1074\/jbc.M112.354373","article-title":"Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors","volume":"287","author":"Kessl","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0725","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00216-010-3737-1","article-title":"Drug-protein binding: a critical review of analytical tools","volume":"398","author":"Vuignier","year":"2010","journal-title":"Anal. Bioanal. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0730","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12551-020-00619-2","article-title":"Theory and applications of differential scanning fluorimetry in early-stage drug discovery","volume":"12","author":"Gao","year":"2020","journal-title":"Biophys. Rev."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0735","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/viro.1999.9727","article-title":"Nuclear localization of human immunodeficiency virus type 1 integrase expressed as a fusion protein with green fluorescent protein","volume":"258","author":"Pluymers","year":"1999","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153092_bb0740","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/hum.2009.051","article-title":"Production of HIV-1 integrase fusion protein-carrying lentiviral vectors for gene therapy and protein transduction","volume":"21","author":"Schenkwein","year":"2010","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153092_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/v13030386","article-title":"A new generation of functional tagged proteins for HIV fluorescence imaging","volume":"13","author":"Mamede","year":"2021","journal-title":"Viruses"},{"issue":"37","key":"10.1016\/j.ijbiomac.2026.153092_bb0750","doi-asserted-by":"crossref","first-page":"24190","DOI":"10.1074\/jbc.273.37.24190","article-title":"A preferred target DNA structure for retroviral integrase in vitro","volume":"273","author":"Katz","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4644(199610)63:1<1::AID-JCB1>3.0.CO;2-3","article-title":"Inverted repeats, stem-loops, and cruciforms: significance for initiation of DNA replication","volume":"63","author":"Pearson","year":"1996","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153092_bb0760","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jmr.970","article-title":"HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations","volume":"22","author":"Mouscadet","year":"2009","journal-title":"J. Mol. Recognit."},{"issue":"Suppl. 3","key":"10.1016\/j.ijbiomac.2026.153092_bb0765","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2047-783X-14-S3-5","article-title":"Raltegravir: molecular basis of its mechanism of action","volume":"14","author":"Mouscadet","year":"2009","journal-title":"Eur. J. Med. Res."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0770","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nat. Protoc."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.153092_bb0775","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1039\/C8CC00090E","article-title":"Selective protein unfolding: a universal mechanism of action for the development of irreversible inhibitors","volume":"54","author":"Askin","year":"2018","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0780","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-0716-0163-1_5","article-title":"High-throughput differential scanning fluorimetry of GFP-tagged proteins","volume":"2089","author":"Sorenson","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153092_bb0785","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1128\/AAC.00717-12","article-title":"Small-molecule inhibitors of the LEDGF\/p75 binding site of integrase block HIV replication and modulate integrase multimerization","volume":"56","author":"Christ","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijbiomac.2026.153092_bb0790","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.aca.2019.12.017","article-title":"A new bivalent fluorescent fusion protein for differential Cu(II) and Zn(II) ion detection in aqueous solution","volume":"1101","author":"Sorenson","year":"2020","journal-title":"Anal. Chim. Acta"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153092_bb0795","doi-asserted-by":"crossref","first-page":"9430","DOI":"10.1038\/s41467-025-64479-8","article-title":"Oligomeric HIV-1 integrase structures reveal functional plasticity for intasome assembly and RNA binding","volume":"16","author":"Jing","year":"2025","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153092_bb0800","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nmeth.2171","article-title":"Improving FRET dynamic range with bright green and red fluorescent proteins","volume":"9","author":"Lam","year":"2012","journal-title":"Nat. Methods"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153092_bb0805","doi-asserted-by":"crossref","DOI":"10.3390\/s16091488","article-title":"A guide to fluorescent protein FRET pairs","volume":"16","author":"Bajar","year":"2016","journal-title":"Sensors (Basel)"},{"issue":"3\u20134","key":"10.1016\/j.ijbiomac.2026.153092_bb0810","doi-asserted-by":"crossref","first-page":"5","DOI":"10.17159\/sajs.2018\/20170324","article-title":"Screening of the NIH clinical collection for inhibitors of HIV-1 integrase activity","volume":"114","author":"Abrahams","year":"2018","journal-title":"S. Afr. J. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153092_bb0820","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026030199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026030199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:30:57Z","timestamp":1787675457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026030199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":163,"alternative-id":["S0141813026030199"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153092","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting HIV-1 integrase: A review of options, challenges and future directions","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"153092"}}